PMC5394614_01
Image of patient's bone marrow biopsy, confirming metastatic melanoma to bone with corresponding PD-L1 staining. Panel a shows images of the patient's bone marrow with extensive involvement by metastatic melanoma. Panel b shows corresponding bone marrow sample with tumor cells staining positive for PD-L1 (Vendor: Cell signal, Clone: E1L3N, Dilution: 1:500)
40425_2017_236_Fig1_HTML.jpg
PMC5394614_01_40425_2017_236_Fig1_HTML.jpg
Fig1
Hematoxylin and eosin staining revealed extensive metastatic melanoma with decreased number of myeloid, erythroid and megakaryocyte lineages along with prominent melanophages (Fig. 1a). PD-L1 staining results using the antibody E1L3N (Vendor: Cell signal, Dilution: 1:500) were positive (Fig. 1b). 
Change in patient blood counts over course of treatment with Pembrolizumab. Panel a indicates changes in patient's white blood cell count (K/mcL) over the period of August 2015 through April 2016. Panel b indicates changes in the patient's hemoglobin level (g/dL) over this same time period. Panel c corresponds to changes in the patient's platelet level (K/mcL) over this same period
40425_2017_236_Fig2_HTML.jpg
PMC5394614_01_40425_2017_236_Fig2_HTML.jpg
Fig2
Laboratory results from 12/10/15 showed improvements in his pancytopenia (Fig. 2), and a CT scan showed decreasing size of his liver lesions with persistent splenic lesions.